Wegovy approved for weight loss in New Zealand

A weight-loss drug called Wegovy has received approval from New Zealand's medicine regulatory body, Medsafe. This drug helps people manage their weight by increasing feelings of fullness and reducing cravings. It was developed by Novo Nordisk and is popular among celebrities in other countries. Associate Health Minister David Seymour supports the approval but criticized the slow process for allowing new medicines. He plans to announce changes to improve the approval pathway later this week. Novo Nordisk aims to make Wegovy available to patients in New Zealand as soon as possible. Wegovy is a prescription injection containing semaglutide, which has been shown to help people lose weight effectively. The European Medicines Agency reports that many users can achieve at least a 5% reduction in their weight. However, potential side effects include headaches, nausea, and diarrhea.